Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of MG-K10 in chronic spontaneous urticaria
CTR20261118Phase 3Active
- Sponsor
- Hunan MaiJi Biotechnology
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of comekibart in chronic idiopathic urticaria (CIU), sponsored by Hunan MaiJi Biotechnology. Started Jun 2026; status: active.
02
Drugs
comekibart
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20261118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261118.